id,group_id,source,exact,prefix,suffix,anno_type,position_type,start,end,tags,all,origin_tags,comment,user,title,created
zGMI0u8kEem4nOvkBvq44w,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER4 can serve as a potential predictive biomarker in trastuzumab treated breast carcinoma,"his study, we evaluated whether ",". We accomplished this by first,",TextQuoteSelector,TextPositionSelector,25300,25390,AMB,no,AMB,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:21:33.526667+00:00
xQx7TutCEemVqaf1dqiPww,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER3,"ning EGFR family members (HER1, ",", and HER4). These proteins are ",TextQuoteSelector,TextPositionSelector,10914,10918,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:46:01.592671+00:00
xAznSO8kEem2JY-dKeETpw,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER4 as a predictive marker in trastuzumab treated breast cancer,"o these challenges, the role of ", remains unconfirmed.In this stu,TextQuoteSelector,TextPositionSelector,25179,25243,NGD,no,NGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:21:19.577522+00:00
wtT54OtDEemMtP9HNz2EZA,3NabqAPM,https://europepmc.org/articles/PMC3858553/,tumors ,ssion ranges from 12% to 82% in ,and has been linked to both impr,TextQuoteSelector,TextPositionSelector,11739,11746,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:53:07.330867+00:00
va8ZJOtCEemNnWeZk4AbdQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER1, remaining EGFR family members (,", HER3, and HER4). These protein",TextQuoteSelector,TextPositionSelector,10908,10912,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:45:49.100413+00:00
uxBCeu8kEemr9UPJthZGzw,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER4 IHC studies in breast cancer have implicated this target as a potential new predictive biomarker in patients receiving anti-HER2,s largely unconfirmed. Previous ," therapy. However, findings from",TextQuoteSelector,TextPositionSelector,24699,24832,YGD,no,YGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:21:04.470657+00:00
s24uQu8kEem8Wp9DPORwxQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/,"HER2 is a well characterized predictive marker in breast carcinoma, the predictive marker status of HER4",ure 1A-C).Go to:DISCUSSIONWhile , is largely unconfirmed. Previou,TextQuoteSelector,TextPositionSelector,24561,24665,YGD,no,YGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:20:51.677008+00:00
qwpnwO8kEem9qxdf85oQbQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/,"Tumor response, Time to progression and Overall survival in Metastatic Trastuzumab treated cohort segregated by HER2 and HER4 ", and B) Overall survival.Table 4,co-expression patternsHER2 & HER,TextQuoteSelector,TextPositionSelector,23078,23204,YGD,no,YGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:20:37.624229+00:00
lsUROutFEemCxzfzPTip0g,3NabqAPM,https://europepmc.org/articles/PMC3858553/,ERBB4,ntitative PCR (RT-qPCR)HER2 and , (HER4) RT-qPCR assays were perf,TextQuoteSelector,TextPositionSelector,36196,36201,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:06:12.365386+00:00
l6-9hutDEemWDbtxIe2A0w,3NabqAPM,https://europepmc.org/articles/PMC3858553/,Tumor,0-551634.02060.61>552451.1927.27," size, cm<2817.0618.182-53166.01",TextQuoteSelector,TextPositionSelector,14783,14788,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:51:54.873295+00:00
l3xO7u8kEem1V4uzdsdwiw,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER4 (E200) IHC staining patterns and scoring in invasive breast carcinoma,igure 1Representative images of ,Open in a separate windowFigure ,TextQuoteSelector,TextPositionSelector,17476,17550,YGD,no,YGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:20:04.903879+00:00
jyGU1O8kEemt20tmSpNDUw,3NabqAPM,https://europepmc.org/articles/PMC3858553/,"breast carcinoma cases, that was quantifiable and likely attributable to differences in HER4",ange of staining intensities in , expression status between patie,TextQuoteSelector,TextPositionSelector,13143,13235,YGD,no,YGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:19:50.867219+00:00
j9g_RutFEem7Zi9IQ7qw2w,3NabqAPM,https://europepmc.org/articles/PMC3858553/,primary tumor,b exposure and resection of the , performed at the Cleveland Clin,TextQuoteSelector,TextPositionSelector,33190,33203,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:06:00.791456+00:00
hr13KOtFEemxM3MstO-VnQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/,invasive carcinoma," based H-score. Briefly, in the ", regions of the histologic secti,TextQuoteSelector,TextPositionSelector,35105,35123,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:05:45.546291+00:00
h2ZuzO8kEemC5He-qbhLfA,3NabqAPM,https://europepmc.org/articles/PMC3858553/,"HER4 antibodies were screened using both cell lines transfected with HER1, HER2, HER3, and HER4; and breast carcinoma",-28].Recently a large number of , samples [29]. The anti-HER4 clo,TextQuoteSelector,TextPositionSelector,12849,12966,NGD,no,NGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:19:37.800198+00:00
gL7-OOs_EemjQHs2SaaERQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER4,2PMCID: PMC3858553PMID: 24091566, expression status correlates wi,TextQuoteSelector,TextPositionSelector,6020,6024,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:22:38.491875+00:00
f20lOu8kEemMr4eGrz6qfA,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER4 and likely plays a critical role in regulating HER2 positive carcinomas and the therapeutic response to HER2 over-expressing tumors,ue localization and function of ,"[11, 18, 19, 24-28].Recently a l",TextQuoteSelector,TextPositionSelector,12666,12802,YGD,no,YGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:19:24.443509+00:00
epp8wOtFEemXPCPcaWwapA,3NabqAPM,https://europepmc.org/articles/PMC3858553/,rabbit,he PATHWAY® anti-HER2/neu (4B5) , monoclonal primary antibody (Ve,TextQuoteSelector,TextPositionSelector,33560,33566,CRT_OG,yes,[CRT_OG][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:05:25.175060+00:00
dmo6qutAEemLUX8HV1BKmg,3NabqAPM,https://europepmc.org/articles/PMC3858553/,EGFR ,erized membrane receptor in the ,family and a therapeutic target ,TextQuoteSelector,TextPositionSelector,9827,9832,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:29:30.666917+00:00
dg5WlO8kEemc-ctgTkwu_A,3NabqAPM,https://europepmc.org/articles/PMC3858553/,"HER4, only one isoform is expressed in breast carcinoma","0, 21]. Of the four isoforms of "," (JM-a) [22, 23]. The expressed ",TextQuoteSelector,TextPositionSelector,12364,12419,YGD,no,YGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:19:08.706045+00:00
cgp-6OtFEemLrBNjO6pWKQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/,AMG,"acquisition. BPP, ZW, ECM, RRT, ",", and GTB performed data analyse",TextQuoteSelector,TextPositionSelector,39921,39924,WT_GP,yes,[WT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:05:10.526413+00:00
bfuqdO8kEemn1vt8wCn02w,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER4 studies in breast carcinoma,llenge of interpreting previous ,", which is the lack of a clinica",TextQuoteSelector,TextPositionSelector,11949,11981,NGD,no,NGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:18:55.129177+00:00
armyqOtFEemPRDdbW9w-QA,3NabqAPM,https://europepmc.org/articles/PMC3858553/,ECM,"B performed data analyses. BPP, ",", and AMG wrote the manuscript. ",TextQuoteSelector,TextPositionSelector,39964,39967,WT_GP,yes,[WT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:04:58.486591+00:00
aKsSBOtAEemR8NsshohknQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/,membrane receptor, (HER2) is a well-characterized , in the EGFR family and a therap,TextQuoteSelector,TextPositionSelector,9802,9819,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:29:07.521008+00:00
ZahUYu8kEemD5jsasvUO1w,3NabqAPM,https://europepmc.org/articles/PMC3858553/,"breast carcinoma, the reported prevalence of HER4 over-expression ranges from 12% to 82% in tumors",. In studies performed on human , and has been linked to both imp,TextQuoteSelector,TextPositionSelector,11634,11732,YGD,no,YGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:18:41.296931+00:00
Ya59JOtFEemAxyev_zAbmg,3NabqAPM,https://europepmc.org/articles/PMC3858553/,B2M,"55525_m1 (HER4), Hs00955525_m1 (","), Hs00984230_m1 (GAPDH), and Hs",TextQuoteSelector,TextPositionSelector,36803,36806,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:04:43.263541+00:00
YWXczutDEemxc5uj19IWiA,3NabqAPM,https://europepmc.org/articles/PMC3858553/,progesterone receptor,"g HER2, estrogen receptor (ER), ", (PR) and Ki-67.Go to:RESULTSDet,TextQuoteSelector,TextPositionSelector,14035,14056,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:50:23.882116+00:00
XCpJ9O8kEemkMANdZJmJ_A,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER2) is a well-characterized membrane receptor in the EGFR family and a therapeutic target in invasive breast carcinoma,H-ScoreGo to:INTRODUCTIONERBB2 (,. Targeted anti-HER2 therapy wit,TextQuoteSelector,TextPositionSelector,9759,9879,YGD,no,YGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:18:25.380955+00:00
XB6eIOtAEemN1uffotNJ-w,3NabqAPM,https://europepmc.org/articles/PMC3858553/, HER2,"rapy.Keywords: Breast carcinoma,",", HER4, Immunohistochemistry, RT",TextQuoteSelector,TextPositionSelector,9683,9688,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:28:46.463128+00:00
X8Hl5utAEemtLFcRoAVJFQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/, HER4,"eywords: Breast carcinoma, HER2,",", Immunohistochemistry, RT-qPCR,",TextQuoteSelector,TextPositionSelector,9689,9694,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:28:52.555471+00:00
WstjhOtDEemxcn9eW0o9Aw,3NabqAPM,https://europepmc.org/articles/PMC3858553/,estrogen receptor ,"tandard markers including HER2, ","(ER), progesterone receptor (PR)",TextQuoteSelector,TextPositionSelector,14011,14029,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:50:12.825356+00:00
VVdmJutAEemhnMuI84YvaQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/,Breast carcinoma,o trastuzumab therapy.Keywords: ,", HER2, HER4, Immunohistochemist",TextQuoteSelector,TextPositionSelector,9666,9682,MIS_DS,no,MIS_DS,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:28:35.181125+00:00
VQbjIutFEem93MMDj9GmZg,3NabqAPM,https://europepmc.org/articles/PMC3858553/,breast cancer,and was applied to two separate , cohorts. In both the neoadjuvan,TextQuoteSelector,TextPositionSelector,31844,31857,WS_DS,yes,[WS_DS][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:04:22.047359+00:00
TzFzqO8kEems9u9rXVKjkQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER4 antibody (E200) and generated a standard clinical HER4 scoring algorithm (HER4 H-Score) utilizing two breast carcinoma,ntly validated high-specificity , cohorts: 1) patients receiving ,TextQuoteSelector,TextPositionSelector,8771,8894,NGD,no,NGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:18:03.609994+00:00
RpduyO8kEem2JOceMjkMhg,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma,2PMCID: PMC3858553PMID: 24091566,"Bryce P Portier,1 Eugen C Minca,",TextQuoteSelector,TextPositionSelector,6007,6141,YGD,no,YGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:17:49.078686+00:00
RZh5AOtFEemPj6N4QYaweg,3NabqAPM,https://europepmc.org/articles/PMC3858553/,BPP,ted in the design of the study. ,", ZW, EM, and CL carried out the",TextQuoteSelector,TextPositionSelector,39835,39838,WT_GP,yes,[WT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:03:56.240065+00:00
P77YuOtEEemi0MPlqgIoMA,3NabqAPM,https://europepmc.org/articles/PMC3858553/,Mets,tasis post trastuzumab therapy (,). Analysis based solely on HER2,TextQuoteSelector,TextPositionSelector,18157,18161,WT_GP,yes,[WT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:56:36.841344+00:00
OtZFdOtFEemqeUP3N5GT2A,3NabqAPM,https://europepmc.org/articles/PMC3858553/,neu,Z) using the PATHWAY® anti-HER2/, (4B5) rabbit monoclonal primary,TextQuoteSelector,TextPositionSelector,33550,33553,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:03:38.080383+00:00
OnMPLOtAEemtUBNOw4LVjA,3NabqAPM,https://europepmc.org/articles/PMC3858553/,metastatic disease,ients receiving trastuzumab for , (n=33). Our HER4 H-Score showed,TextQuoteSelector,TextPositionSelector,9012,9030,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:27:49.927905+00:00
N_4FvutDEemxMSNt5uwb7w,3NabqAPM,https://europepmc.org/articles/PMC3858553/,antibodies,Recently a large number of HER4 , were screened using both cell l,TextQuoteSelector,TextPositionSelector,12867,12877,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:49:14.438741+00:00
LW4nbOtAEemsez9nBEaA3A,3NabqAPM,https://europepmc.org/articles/PMC3858553/,antibody,validated high-specificity HER4 , (E200) and generated a standard,TextQuoteSelector,TextPositionSelector,8789,8797,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:27:28.138982+00:00
LT3kWOtFEem3-LN8JPEvKw,3NabqAPM,https://europepmc.org/articles/PMC3858553/,tumor,robe signals were counted in 40 , nuclei per case under a fluores,TextQuoteSelector,TextPositionSelector,38559,38564,MIS_DS,no,MIS_DS,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:03:15.294887+00:00
HbXNSOtFEemXOz_J4a6sBg,3NabqAPM,https://europepmc.org/articles/PMC3858553/,TFRC,"_m1 (GAPDH), and Hs03929097_g1 (",") (Applied Biosystems, Foster Ci",TextQuoteSelector,TextPositionSelector,36851,36855,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:02:49.263967+00:00
HHPRcOtDEem3Ys9cteTbpA,3NabqAPM,https://europepmc.org/articles/PMC3858553/,carcinomas,ole in regulating HER2 positive , and the therapeutic response to,TextQuoteSelector,TextPositionSelector,12745,12755,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:48:28.144069+00:00
EEju4O8lEemN1Wda2Stb_g,3NabqAPM,https://europepmc.org/articles/PMC3858553/,"invasive breast carcinoma are limited and include ER, PR, Ki67, and ERBB2 (HER2", predictive markers utilized in ,"). In the case of HER2, over-exp",TextQuoteSelector,TextPositionSelector,8181,8260,YGD,no,YGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:23:27.459642+00:00
E2zpeutFEemkVMNZ2jSdCQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/,GAPDH,"955525_m1 (B2M), Hs00984230_m1 (","), and Hs03929097_g1 (TFRC) (App",TextQuoteSelector,TextPositionSelector,36824,36829,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:02:32.098368+00:00
DfCxeutAEem155OqTXKEvw,3NabqAPM,https://europepmc.org/articles/PMC3858553/,breast carcinoma,hm (HER4 H-Score) utilizing two , cohorts: 1) patients receiving ,TextQuoteSelector,TextPositionSelector,8891,8907,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:26:35.345635+00:00
CJH0tOtAEemYi3fPS4R1iQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER2,"nclude ER, PR, Ki67, and ERBB2 (","). In the case of HER2, over-exp",TextQuoteSelector,TextPositionSelector,8269,8273,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:26:26.261637+00:00
AcqmWOtAEemC7RP_zVeGew,3NabqAPM,https://europepmc.org/articles/PMC3858553/,ERBB2,"d and include ER, PR, Ki67, and "," (HER2). In the case of HER2, ov",TextQuoteSelector,TextPositionSelector,8262,8267,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:26:14.905633+00:00
9ngecOs_EemXQQvgdH3NAQ,3NabqAPM,https://europepmc.org/articles/PMC3858553/,Ki67,"are limited and include ER, PR, ",", and ERBB2 (HER2). In the case ",TextQuoteSelector,TextPositionSelector,8252,8256,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:25:55.909866+00:00
9a49qOtEEemMtSvhZk9wSg,3NabqAPM,https://europepmc.org/articles/PMC3858553/,Ki-67, progesterone receptor (PR) and ,.Go to:RESULTSDetermination of H,TextQuoteSelector,TextPositionSelector,14066,14071,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T10:01:42.164442+00:00
8gMW7Os_EemXQHPYPEwzrg,3NabqAPM,https://europepmc.org/articles/PMC3858553/,PR,"oma are limited and include ER, ",", Ki67, and ERBB2 (HER2). In the",TextQuoteSelector,TextPositionSelector,8248,8250,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:25:48.438763+00:00
7g-4JOs_EemtbTsUUcZuFw,3NabqAPM,https://europepmc.org/articles/PMC3858553/,ER,rcinoma are limited and include ,", PR, Ki67, and ERBB2 (HER2). In",TextQuoteSelector,TextPositionSelector,8244,8246,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:25:41.897203+00:00
6doVAO_6Eem1wBtm6Q3DZw,3NabqAPM,https://europepmc.org/articles/PMC3858553/, invasive breast carcinoma,and adjuvant Trastuzumab treated,"Bryce P Portier,1 Eugen C Minca,",TextQuoteSelector,TextPositionSelector,6115,6141,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-16T09:54:15.347457+00:00
5svoVu8kEemvz89LWhSm2Q,3NabqAPM,https://europepmc.org/articles/PMC3858553/,"HER4 studies, we chose to standardize a single antibody and use a semi-quantitative scoring system for HER4 expression in breast carcinoma",bserved in previous qualitative ,. To assess the analytical sensi,TextQuoteSelector,TextPositionSelector,26387,26525,NGD,no,NGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:22:17.785360+00:00
3igpeutCEemqeFO7ue0sWg,3NabqAPM,https://europepmc.org/articles/PMC3858553/,human,"4, 15]. In studies performed on "," breast carcinoma, the reported ",TextQuoteSelector,TextPositionSelector,11641,11646,CRT_OG,yes,[CRT_OG][ALL],,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-10T09:46:43.610654+00:00
3QT6JO8kEemDVt8SQw5w2Q,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER4 H-Score in two invasive breast carcinoma,ression assay. We evaluated our , cohorts that received trastuzum,TextQuoteSelector,TextPositionSelector,25838,25883,NGD,no,NGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:22:01.553073+00:00
1QInNO8kEemNFxuDg-Ipiw,3NabqAPM,https://europepmc.org/articles/PMC3858553/,HER4 antibody (E200) which was recently stringently tested and validated in breast carcinoma,"is by first, utilizing a single "," and second, by developing a sta",TextQuoteSelector,TextPositionSelector,25442,25534,NGD,no,NGD,,acct:vaishnavijpai@hypothes.is,HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.,2019-10-15T08:21:48.019269+00:00
